Several years ago physicians heard the advice, "If we do not develop guidelines, some regulatory agency of the government will do it without our input." Many of us accepted this challenge and invested substantial energy in quality assurance activities in the attempt to keep clinical decisions within the profession.
The pursuit of quality in medicine has been a worthwhile endeavor. What physician would not agree with David Eddy' that making "wise decisions and careful performance" is in the best interest of both patient and doctor? However, this has not prevented the insurance industry from writing its own competing standards, which I call "reimbursement guidelines." Let us review the basic differences between quality care from the medical and payor perspectives.
Quality Assurance
The prime motivation for improvement in quality came from the Joint Commission on Accreditation of Healthcare organization^,^.^ when it mandated each hospital department to establish formal quality assurance plans in the late 1980's. This mandate gave administrative power to counsel doctors if justification for care was not properly documented. Physicians could no longer recommend procedures and tests just because they were available. Acceptable reasons had to be documented and illogical decisions had to be defended. This led to the development of quality assurance (QA) and clinical 0194-5998/93/$1.00 + .10 23/1/48581 indicators, which initially focused on short justifications for surgery, but, in the case of our Academy, have become more inclusive. It also led to the American Medical Association's advocacy for development of practice parameters, which are comprehensive, extensively documented management protocols for diseases and treatments.
The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) 1992 Clinical Indicators recommend a logical argument to demonstrate the validity of the diagnosis. We advise consideration of historic criteria (including age, disability caused by disease, medical management), physical examination, and any pertinent laboratory data that would affect the decision to perform surgery. The concept of writing a logical justification is not new; it is as old as medicine. Yet, its application by busy practitioners became sorely neglected over the years, and those of us who review charts continue to see evidence of poor documentation.
Continuous Quality Improvement
Currently we are beginning to supplement quality assurance with continuous quality improvement (CQI). The purpose here is not to single out individuals whom Benvick4 calls the "bad apples." Rather, it is a way of examining multidisciplinary systems that permit or prevent inappropriate decisions and actions to occur. In CQI we compare the action with the expectation.
One of the tools used for measurement in CQI is the clinical or critical pathway. This tool was first used by industry in the 1950's and is now used to coordinate patient care and facilitate communications by listing various activities and time required through completion. From Massachusetts Eye and Ear Infirmary Ruth Walton, RN, reports*: "We have shortened the length of stay from 15 to 11 days without any compromise in laryngectomy patient At Community-General Hospital in Syracuse, where I practice, clinical pathways are being developed for all otolaryngologic ambulatory surgical procedures and are due to be tested for validity during summer 1993. In these pathways we will examine preoperative, day of surgery, and 24-hour postoperative activities. We will also compare procedure justification with our QA protocols and review outcomes. This approach extends the clinical pathway beyond the week of surgery because, unlike inpatient surgery, only a few hours' worth of postoperative care and outcome information is available in the ambulatory center record.
Outcomes Research
Perhaps the most promising approach to improving quality is the study of outcomes. According to Dr. George Gates,f Chairman of the AAO-HNS Informatics committee, "There are increasing pressures. . . to demonstrate effectiveness in more subjective terms such as reduction of symptoms, restoration of function, alleviation of psychosocial distress and satisfaction with care. Further, there are disorders for which value of treatment is debated or for which competing, seemingly effective treatment regimens are advocated." Accomplishing this task will require national clinical network linked by computers to a central office for data analysis. The first project is obstructive sleep apnea; it is "a common problem, management is controversial and varied across the country, factors that determine successful surgical therapy are not fully known, and there are important economic considerations."
Reimbursement Guidelines
While the medical profession focuses on methods to improve clinical decisions to discourage unnecessary or ineffective procedures and tests, the insurance industry considers this approach insufficient to reduce health care costs. One of our members reports, "When I submitted our national guidelines to an insurance company, it did not think they were stringent enough."* Currently there are at least three methods of cost control used by insurers and managed care organizations. The first is to discount the usual and customary fee. The second is to restrict the number of * Roper A. Personal communication, March 3, 1993. providers (physicians) allowed to render services for a specific managed care organization. The third is to reduce the number of reimbursable procedures without jeopardizing health or outcomes. For instance, if the condition is infection, then perhaps a longer trial of antibiotic will suffice. If there is snoring possibly due to a large uvula or deviated nasal septum, a decision can and has been made that this is a social concern, not a disease, and therefore not reimbur~able.~ In other words, availability of a specific treatment is not reason enough for automatic reimbursement if less expensive options are available.
I recently compared three reimbursement guidelines with the clinical indicators published by the AAO-HNS. It is not an easy task because of differences in wording and interpretation. Let us take a single indication as an example.
The AAO-HNS 1992 Clinical Indicators received input from the Committee on Tonsils and Adenoids. Among the several criteria recommended for removal of tonsils was a history of four or more infections in 12 months. According to one insurance plan6 the requirement is six infections during 12 months, unless a single infection lasts 30 days and during that time a cephalosporin or penicillin antibiotic failure was followed by an unsuccessful antianaerobic medication. Another plan' accepts the four-infection criterion if the child is under 3 years old. However, the older child must also have either five infections of average severity or four infections of greater severity, such as a history of "hospitalization for tonsillitis, or absence from school for 2 or more weeks, or confinement to bed with 3 or more days of fever during each episode." A third provider8 requires patients to have 30 days of continuous infection treated by two courses of antibiotic. When faced with such an array of considerations, no wonder physicians and patients are confused, frustrated, and angry.
Is There Hope?
Two options are already available to relieve some of the tension created by the conflict of interests between the medical profession and the insurance industry. The first is better communication, a willingness to discuss mutual concerns at a high organizational level. It certainly worked last fall in California, when representatives of the state otolaryngology society were able to discuss guideline development with Blue Shield of California and negotiate criteria for functional endoscopic sinus surgery that are acceptable to both sides.' This winter the AAO-HNS accepted an opportunity for several distinguished members of our specialty to act as consultants in the development of reimbursement screening tools with a major developer for the insurance industry. This will give us input and access to decisions of major economic and clinical importance.
A second opportunity will occur when comprehensive, well-designed outcome studies are published. These will solve the dilemma over whose criteria shall prevail. It is not enough for one interest group or another to mandate rules and guidelines. The true test for appropriateness is the collective experience of all parties, including the patient.
